Acromegaly

• FDA label_change · 2021-01-19
  FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)

  The FDA approved a supplemental application for bromocriptine mesylate from Zydus Pharmaceuticals USA Inc., resulting in labeling changes fo…

• FDA label_change · 2020-07-09
  FDA Approved: SIGNIFOR LAR — Supplemental Application (Recordati Rare Diseases, Inc.)

  FDA approved a supplemental application for SIGNIFOR LAR (pasireotide) submitted by Recordati Rare Diseases, Inc., to modify the product lab…

• FDA label_change · 2018-08-27
  FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  The FDA approved a supplemental application for Octreotide Acetate submitted by Hikma Pharmaceuticals USA Inc., updating the product labelin…

• FDA label_change · 2013-06-12
  FDA Approved: CYCLOSET — Supplemental Application (Avvisto Therapeutics LLC)

  The FDA approved a supplemental application for CYCLOSET (bromocriptine mesylate) submitted by Avvisto Therapeutics LLC. The action involves…

• FDA label_change · 2011-09-30
  FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA supplemental application for Sandostatin LAR Depot (octreotide acetate) submitted by Novartis Pharmaceuticals Corporation, involving cha…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.